This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk02: Good afternoon and welcome to the Q3 2021 Knowles Corporation earnings conference call. My name is Emma and I will be your conference operator today. At this time, I would like to welcome everyone to the conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by one on your telephone keypad. If you would like to withdraw your question, again, press star one. With that said, here with opening remarks is NOLS Vice President of Investor Relations, Mike Knapp. Please go ahead.
spk01: Thanks, Emma, and welcome to our Q3 2021 earnings call. I'm Mike Knapp, and presenting with me on the call today are Jeffrey New, our President and CEO, and John Anderson, our Senior Vice President and CFO. Our call today will include remarks about future expectations, plans, and prospects for NOLS, which constitute forward-looking statements for purposes of the Safe Harbor provisions under applicable federal securities laws. Forward-looking statements in this call will include comments about demand for company products, anticipated trends in company sales, expenses and profits, and involve a number of risks and uncertainties that could cause actual results to differ materially from current expectations. The company urges investors to review the risks and uncertainties in the company's SEC filings, including but not limited to the annual report on Form 10-K for the fiscal year ended December 31, 2020, periodic reports filed from time to time with the SEC, and the risks and uncertainties identified in today's earnings release. All forward-looking statements are made as of the date of this call, and NOLS disclaims any duty to update such statements except as required by law. In addition, pursuant to Reg G, any non-GAAP financial measures referenced during today's conference call can be found in our press release, posted on our website at NOLS.com, and in our current report on Form 8K filed with the SEC including a reconciliation to the most directly comparable GAAP measures. All references on this call will be on a non-GAAP continuing operations basis unless otherwise indicated. Also, we've made selected financial information available on the webcast slides, which can be found on the IR section of our website. With that, let me turn the call over to Jeff, who will provide some details on our results. Jeff.
spk07: Thanks, Mike, and thanks to all of you for joining us today. For Q3, we reported revenue of $233 million above the midpoint of our guidance and up 13% from the year-ago period, driven by strong demand across our audio and precision device segments. Gross margins improved to 41.8% near the high end of our guidance range, and our earnings per share was $0.45 above the high end of our expectations. In audio, revenue was up 8% from the year-ago period as hearing health sales increased on strong end-market demand and MEMS microphone sales grew, driven primarily by IoT. Precision Device delivered record revenues again in Q3, up 35% from the year-ago period, driven by improved demand across a broad range of end markets we serve and an acquisition we completed in Q2. We also delivered cash from operations of $56 million. Overall, another strong quarter that demonstrates the benefit of our investment in differentiated products to increase revenue across a diverse set of growing end markets driving gross margins higher and delivering strong earnings and cash flow. Let me now spend some time detailing the trends we are seeing by the end markets in each one of our business segments. In audio, we saw broad-based improvement year-over-year in MEMS microphone sales, despite experiencing supply constraints. Hearing health sales also increased from the year-ago period on strong end market demand. As we look forward, we believe recently proposed rules from the FDA on over-the-counter hearing aids, if adopted, will make it easier for people with mild hearing loss to have access to technology to improve quality of life. We expect this new channel to bolster our growth in hearing health over the years to come. We are increasing our capacity to service our traditional hearing aid market and the opportunities for the over-the-counter and true wireless markets. Moving on to precision devices. sales reached record levels again in Q3 with significantly improved gross margins as demand from MedTech, industrial, defense, and electric vehicle markets drove strong year-over-year improvement. We continue to develop advanced solutions for mission-critical applications that rely on our high-performance capacitors and RF filters, which is yielding solid results. In high-performance capacitors, the MedTech market drove a significant portion of the year-over-year growth, as demand improved for our high-reliability products used in implantable devices and MRI machines. We are also beginning to see a broadening of our customer base in Asia and Europe as high-voltage EV platforms begin to go to production. In our filters, our products continue to see strong demand from defense customers in North America and Europe for communications and radar solutions. We are also beginning to see a number of new design opportunities in 5G millimeter wave telecom, and we secured several prototype orders for small cells and repeater equipment. For the third consecutive quarter, we saw record bookings in PD across a wide array of products, giving me confidence we can grow precision device revenue by greater than 15% this year, with the bulk of the growth being driven by organic initiatives. In a moment, John will discuss the Q3 results and the Q4 guide in more detail, but our revenue growth is currently being held back by a number of short-term issues that have recently been in the headlines, which include extended lead times and capacity constraints on semiconductors, and more recently, power disruptions in China, as well as some lingering COVID uncertainty. For the past several years, our strategy has been to focus our R&D investments, capacity expansions, and acquisitions in products for growing markets that value our differentiated solutions. This is paying dividends today as gross margin continues to expand, driving increased operating income and cash flows. As these headwinds start to dissipate, we expect the impact of our strategy to be even more pronounced on our financial results. Our team has delivered three strong quarters so far this year. I believe our leadership positions across the markets we serve and our strategy to deliver high-value solutions to a diverse set of growing end markets positions us well for the rest of 2021 and beyond. With that, I'll turn it over to John to expand on our financial results and provide the guidance for the fourth quarter. John?
spk06: Thanks, Jeff. We reported third quarter revenues of $233 million, up 13% from the year-ago period, driven by increased shipments in both the audio and precision device segments. Audio revenues of $178 million were up 8% due to higher demand for MEMS microphones across mobile and non-mobile end markets and stronger hearing aid sales. Precision Devices delivered record revenues of $55 million, up 35% year-over-year, as a result of organic growth of 21% and an acquisition completed in the second quarter of 2021. Third quarter gross profit margins were 41.8%, near the high end of our guidance range and up more than 500 basis points versus the same period a year ago. Audio segment gross margins improved more than 450 basis points, driven by productivity gains, higher factory capacity utilization, and favorable product and customer mix. In the precision devices segment, gross margins were more than 600 basis points above prior year levels due to productivity gains, improved factory utilization, favorable inventory reserve adjustments, and an acquisition, partially offset by higher precious metals cost. RD expense in the quarter was $20 million, up slightly from the year-ago period, but lower than expected, due to the timing of new hires. SG&A expenses were $27 million, in line with our guidance range, and up $1 million from the prior year, driven primarily by higher incentive compensation cost and an acquisition, partially offset by lower legal expense. For the quarter, adjusted EBIT margin was 22.6%, above the high end of our guidance range, and up more than 8 percentage points from the same period a year ago, driven by higher gross profit margins, improved operating leverage, and favorable FX impacts. EPS was $0.45, above the high end of our guidance range, and up $0.21 from the prior year. Further information, including a detailed reconciliation of GAAP to non-GAAP results, is provided in the financial tables of today's press release and can also be found on our website at knolls.com. Now I'll turn to our balance sheet and cash flow. Cash and cash equivalents totaled $140 million at the end of Q3. Cash generated by operations in the quarter was $56 million, above the high end of our guidance due to higher EBITDA and lower than expected net working capital. Capital spending was $12 million in the quarter. Given our existing cash position and our expectations that we will continue to generate significant free cash flow in the future, we will settle the principal amount of the convertible notes, which mature next month, in cash. Moving to the fourth quarter, we expect total company revenue to be between $230 and $235 million, down 4% at the midpoint versus the same period a year ago. Revenue from the audio segment is expected to be down approximately 14% from Q4 2020, driven by timing of customer product launches and supply chain constraints, resulting in reduced MEMS microphone shipments, partially offset by higher hearing health revenues. Precision device revenue is expected to be up more than 40% versus the prior year, driven by strong organic growth in the defense, medtech, and industrial end markets, and the acquisition completed in the second quarter of this year. We have to make total company gross margins for the fourth quarter of 40% to 42%, up 300 basis points from the year-ago period, driven by higher capacity utilization, favorable product mix, and the acquisition completed in Q2. Our gross margin expansion through the first three quarters of 2021 demonstrates the execution of our strategy to deliver high-value, differentiated solutions to our end markets. We expect total company gross profit margins will reach approximately 41% for full year 2021, a record high and approximately 200 basis points above 2019 levels. R&D expense in Q4 is expected to be between $19 and $21 million. flat with prior levels. We're projecting selling and administrative expense to be between $27 and $29 million, up $1 million from the year-ago period, driven by higher incentive compensation costs and the impact of the acquisition completed earlier this year. Adjusted EBIT margin for the quarter is expected to be approximately 21%. is expected to be within a range of 43 to 45 cents per share. This assumes weighted average outstanding shares during the quarter of 95.6 million on a fully diluted basis. Despite the near-term supply chain challenges, which are impacting revenue, our actions to improve gross margins, coupled with our discipline over operating expense spending, is resulting in an expected increase in full-year EPS of nearly 40%. above 2019 levels. We're forecasting an effective tax rate of 8% to 12% for the quarter. This range includes a discrete tax benefit related to the filing of our 2020 federal tax return. Going forward, due to the potential expiration of a tax holiday at the end of 2021, our future expected effective tax rate may increase to 14% to 18%. We're expecting cash generated by operations in Q4 to be between $45 and $55 million, and capital spending to be approximately $20 million. Please refer to our press release and to our Form 8K filed today with the FCC for a GAAP to non-GAAP reconciliation. I'll now turn the call back over to Jeff for closing remarks, and then we'll move to the Q&A portion of the call. Jeff? Thanks, John.
spk07: We are increasingly confident about our near and longer-term prospects as our strategy to deliver high-value, differentiated solutions to a diverse set of growing-end markets is in allowing us to expand gross margins while driving operating income and producing strong cash flow. We will continue to drive shareholder value through investment in high gross margin products, accretive acquisitions, and stock buybacks. Before we move to the Q&A, I would like to announce we are planning on hosting an investor call in late November to provide an update on our growth opportunities and our capital allocation strategy, as well as provide new mid-term financial targets. More detail will follow in the near future, and we are excited about the opportunity to share our plans for revenue growth and gross margin expansion and what it means for operating margins and cash flow. With that, I'll turn it over to open for Q&A.
spk02: At this time, I would like to remind everyone, in order to ask a question, press star, then the number one on your telephone keypad. We'll pause for just a moment to compile the Q&A roster. Your first question comes from the line of Bob Blavik with CJS Securities. Your line is now open.
spk03: Good afternoon. Congratulations on a nice quarter.
spk02: Thanks, Bob.
spk03: I want to dig in on a few things you mentioned earlier. As it relates to the supply chain, can you give us kind of a sense of how much of it is international labor, chip shortage, and roughly how big a revenue hit it is? And then going from there, how long do you think this will impact you and your customers looking ahead?
spk07: Yeah, so first I'll just make a comment. I think we are being cautious in our guidance that we're providing. I think You know, right now we're kind of in the midst of this, and, you know, without, you know, going through a ton of detail, you know, I would probably estimate in 2021 this is probably 15 million plus. In the back half of the year. In the back half of the year, yeah. You know, so, you know, some of it's in Q3, majority in Q4, but I think, you know, I think that's probably about a number, 15 million plus. It's hard to say. Again, we're obviously working with our suppliers. I think it's mainly semiconductor. I wouldn't call at this point that we're having major labor shortages or issues like that. We have had some downtime on power in China, which had some impact for us in early Q4, late Q3. Some of that seems to have passed right now, but we'll see how that continues the rest of the quarter. But again, we're being cautious. And I would sit there and say right now I kind of view this, you know, these things are going to linger around in the Q1 for sure, maybe, you know, possibly in the Q2. And that's when we start to see these things, we start to see these things start to clear up. You know, again, I'm not going to call this exactly, Bob, but that's kind of what we see right now.
spk03: Got it. Okay, great. Now that's great and helpful color. And then you mentioned the hearing health of the ear, you know, over-the-counter markets. Can you maybe give us a sense of where the FDA is, how long this could take to be an opportunity for you, and how big the market opportunity might be for you?
spk07: Yeah, I'm not going to speculate on what the government's going to do. I'm just going to talk about how we see this market, though, Bob, and how we see it is it's incremental. And here's why we see it this way, and I think I've talked about this on other calls, but if you look at that pyramid that we talk about of hearing loss, profound hearing loss, significant hearing loss, mild hearing loss. The most underserved portion of that is mild hearing loss, and that's also the largest portion of people who have hearing loss. And this is where we think this is going to be targeted. We have some customers who have introduced over-the-counter products already into the marketplace and are being sold today. And I think there's a couple points I would make is, number one is, at least preliminarily, People who are buying very early days, over-the-counter hearing aids, the average age is much younger than the traditional hearing aid channel, to the tune of 10 to 15 years younger. And I think the positive that is for us, number one, is it brings somebody into the idea of improvement of quality of life significantly earlier in their life, and that allows for us to have, again, multiple cycles of technology and buys of hearing aids over time. So it increases the TAM. It really increases the TAM, both because you're bringing new hearing loss people in, but also at a younger age. And so to speculate on how big this market is, I would probably say that the overall hearing aid market is roughly 15 million units a year. That's kind of the rough size of the market. I would be probably thinking next two to three years, this could be a couple million, two, three million hearing aids a year. And we're very encouraged, last piece, about the idea here that if you look at people who have introduced products to the market, they're not focused on cost. They're focused on performance. And that's a really important point for us, right? We want people who are focused on performance, right? Because, first of all, you don't want to turn people off with their first experience with a hearing aid by buying something cheap, but also because they value our high-value products, whether it be in microphones or in our speakers and receivers.
spk03: Okay, great. Thanks. Then one last one and I'll get back in queue, but obviously showing a lot of success in the precision device market and both organically, but through acquisitions you've made in the past too. Can you just give us a sense of the M&A environment out there and if there's opportunities for you with your pristine balance sheet now to continue to make some acquisitions in precision device?
spk07: Yeah, I would say that the funnel is pretty active. We're very active within an M&A area. But on the reverse side, I would also say the valuations are quite high. And I think from my perspective, it's really important, especially at the type of valuations that we're extremely disciplined about what we're going to do. I think the acquisition that we did earlier this year has been very successful. The three or four other ones that we did over since 2017 have all been successful. We want to keep up that track record. And I think the point I would just say is I'm hopeful that we can get some more acquisitions done over the next 18 months. But just keep that in mind is that we are trying to be very disciplined about valuation.
spk03: Got it. Super. All right. Thanks very much.
spk07: Thanks, Bob.
spk02: Your next question comes from the line of Sugi De Silva with Roth Capital. Your line is now open.
spk04: Hi, Jeff. Hi, John. Congrats on the cash generation and the margin execution here. So, yeah, so first thing, maybe on the gross margin since we're there, what are some of the key factors that are driving this? I know you have an event coming up to talk about it, but, you know, how sustainable is some of the improvement that you've seen?
spk06: Yeah, no, good question, Sugi. You know, in terms of the audio segment, year over year, our gross profit margin improvement is really driven by, to a great extent, is mix. Specifically, a higher proportion of MEMS microphones ship for non-mobile applications. Also, growth in the hearing health business. Those are both probably the key drivers. Obviously, we're also running our factories at pretty high levels, you know, 90% plus in terms of capacity utilization. I'd say those are probably the main things. We've also been really successful. We're paying a higher price for chips. We've been pretty successful at passing those costs on to our customers. With PD, I think it's similar. Mix is really helping. Higher proportion of sales going into higher margin medical and defense applications. Then they've really made a lot of progress on productivity gains. within the factories, and really optimal lot sizes, reducing scrap and excess in inventory. So it's some blocking and tackling, but it's also some really favorable mix.
spk07: Yeah, and so let me just make a little bit broader top line, giving you the detail, like what's going on right now. But again, I think if you talked about this, Suji, over the last couple quarters, the three, four quarters, about where we're investing our R&D resources, where we're investing our CapEx, and we're really trying to focus this in. on non-commoditized products, right? And then what's happening is as we get more of these products into the marketplace, we spend more money in these areas, you're seeing that in terms of the mix.
spk06: Just to finish up, too, with respect to, you know, I noted in my script that I'm confident that we'll be at or maybe even slightly above 41% for full year 2021. If it's investor call we have later in the quarter, we'll talk about opportunities to expand gross margins further.
spk04: Okay. Look forward to that, John. And then a couple questions on the supply constraint. In terms of the lead customer and the mics, I'm wondering if the ordering patterns would kind of have some of the ordering that might have happened in the fourth quarter push out to the first quarter, if that's not the way this would play out given the constraints? Any color there would be helpful.
spk07: Yeah, I'm not going to comment specific to one customer, but here's what I'd say. Relative to that, we all know that the timing of the launch is slightly off from last year. It was delayed. There was COVID-related issues this year. It was earlier. I think this is more like a traditional pattern. But I think, let me just speak generally, and again, not to a specific customer, but, you know, I would say first, the $15 million that I kind of said earlier that we could have shipped more is what we are being constrained by. I'm not trying to quantify here what our customers are being constrained by. And there's clearly some constraints out there in certain applications with certain products. across the customer base, but that's not even quantified in the $15 million. The $15 million for the back half is really what we think we could have shipped more if we could have gotten or built more microphones.
spk04: Okay, that's helpful clarification. And then lastly on PD, the booking visibility is very strong there. I'm wondering if any component of that is related to supply constraints and customers trying to cover their supply needs or how much of that versus... the growth in the bookings that's really driving that?
spk07: I would say the vast majority of the growth, we don't see it that way. And let me just kind of frame the doubt here. You know, we kind of have an industrial distribution kind of piece of business. That one piece within PD, there could be some more ordering than we normally would see. But when you start thinking about defense or aerospace, the majority of this is all custom product. They're ordering for, and we don't really have a supply constraint in that area. The life sciences stuff, I don't see that. I don't think that's, there's a lot of custom there. Automotive, again, custom. I don't really see this, at least in our minds, that the vast majority of the growth, and again, I would say this industrial slash distribution business, which ends up being about 15% of the business that area could be expanding at a faster rate maybe than actually the demand is there. But the rest of the business I think is pretty solid. Okay. Thanks for the call, Jeff.
spk02: Your next question comes from the line of Tristan Guerra with Baird. Your line is open.
spk05: Hi. Good afternoon. You talked about passing higher costs to customers, and could that, provide a fairly different pricing outlook for next year? In other words, you know, could pricing be up next year as a result, and should we view this as a top-line contributor?
spk07: Well, I guess what I would say is that I think it's a little too early to make that call yet. I think we're going to have to see after, as we get through, and I always pick this point in time, We've got to get through the holiday season here in the U.S. and then Chinese New Year and then see where things stand. I mean, in spite of everything that's going on, China's still weak for us. I mean, it's still weak for us. We'll see how this kind of develops as we get closer to Chinese New Year. But it's still quite weak. And I would say when we talk a lot about Mems Mics in the pricing environment and passing on costs, But the pricing environment, in my mind, in both PD and hearing health, has been reasonably favorable. So I think overall, again, and I guess this goes back to what we said a few questions ago, is that the more we focus on non-commoditized portions of our market, the more positive the pricing will become and growth margin will be better.
spk05: Okay, great. And then any update on the balance armature speaker and where you stand in terms of finalizing that automated factory in the Philippines?
spk07: I'm glad I got that question, Tristan. So, yeah, so the team is there. I just saw actually a video with the first products coming off the line. You know, obviously this is not fully qualified yet, but we're expecting to be shipping to customers this quarter. So that's the expectation right now, that in Q4 we'll start shipping off the automated line. Yeah, and if you think about it, as I said before, it's been touch and go for so long. And I thank the teams that have gone there. By the way, just the teams, maybe there's some that are listening that are in the Philippines. They had a quarantine for seven days when they got there before they could go into the factory, which I know is a tall pain in the neck. And so I appreciate the teams willing to go there and do that. But we expect that, you know, as design winds start to ramp, we probably won't see full utilization of the capacity, you know, in the first half of next year. And they'll start ramping, you know, closer to full utilization in the back half of 22.
spk00: Great.
spk05: Very useful. Thank you.
spk02: Your next question comes from the line of Christopher Rowland with Sasquahanna International. Your line is now open.
spk00: Hi, good afternoon. This is actually on for Chris. I just want to follow up on the gross margin question. Obviously, a great progression here, but I'm curious how much more upside the utilization can bring to the table. You already said 90 plus percent right now. Yeah, we're also... Go ahead. Yeah, and the hearing health part as well, seems like it's already recovered quite a bit. So what are some of the other drivers that could help you to get to that 42% target?
spk06: Yeah, as I mentioned, we're going to give a little more clarity and color on future gross margin expansion. There's a few levers that we'll talk about. Mix is one of them. Higher growth in, I'll call it the hearing health, the precision device, the non-mobile MEMS mic business, that's one. But we'll elaborate a little more on those drivers.
spk07: Let me make a couple comments. I think, number one, new products will obviously, across all of our businesses, will drive that, number one. Number two is I think we've talked pretty extensively, you know, in our business, we're really not intent on adding capacity to maintain commoditized products of selling. And so I think, you know, that keeps going back to, you know, obviously there's mix within, you know, what products we're selling. But there's also the fact that we kind of see is that lower gross margin business kind of falls off the bottom. And we've talked about things like dye sales to be able to service those types of markets. We do think there is some opportunity yet for gross margin expansion. And as John said, we'll go through those details on the investor call. We'll have it in late November.
spk00: Sounds good. And then On the inventory side, seems like for the past couple quarters you've been building internal inventory, but this quarter it was down by 24 days. Would you say you're in a comfortable range right now, and should we interpret this as strong demand overall, or is it more supply constraints kicking in?
spk07: I think it's a little bit of both. I mean, we do have definitely supply constraints on certain product categories where, you know, if we could build more, we would. And we're, I would say, closer to hand-to-mouth on inventory on certain products. On the other side, I think, you know, inventory being down, you know, there is, beyond the supply constraints, beyond the supply constraints, there's the issue of this normal seasonality where I think we go through with, you know, in Q1, Q2, we bring raw materials in. And Q2 into Q3, we build the product. And then, you know, we have our strongest quarter typically, you know, either in Q3 or in Q4, which draws inventory down. So this is following kind of the normal path that we saw. But we are having constraints that allow us not to build as much as we'd like.
spk06: One other point I'd add is, too, that's kind of unique to this year is we're transitioning, and our MEMS microphone business, transitioning to 8-inch. So we're carrying a little extra inventory. I'd expect that to go down kind of mid-2022.
spk07: Yeah, and further point, I would sit there and say, you know, at this point, you know, I think we talked about utilization. Because of supply constraints, we are not running in our microphone business at full capacity right now. We are not running at full capacity right now.
spk00: Sounds good. Thank you very much.
spk02: At this time, there are no further questions. Mr. Knapp, I turn the call back over to you.
spk01: Great. Thanks, Emma, and thanks to everyone for joining us today. As always, we appreciate your interest in those. We're also going to be participating in the Roth Conference on November 18th and a Wells Fargo Conference on December 2nd. So we hope to speak with you then or on our next earnings call, and we'll also have more information out on our investor update later in November. So thanks and goodbye.
spk02: This concludes today's conference call. You may now disconnect.
Disclaimer